
Global Drug Delivery Challenges Explained
In this episode of Bio Break, Nick Allan and Nigel Syrotuck dive into the surprising realities of global drug delivery. While medical devices often dominate development conversations, the way drugs are delivered across regions can dramatically change how treatments succeed — or fail.
Nigel reflects on a trip to Italy where food sparked thoughts about oral drug delivery. In regions like Italy, pills and tablets are the most common approach. Larger countries also tend to prefer simple, scalable methods such as pills or injections. By contrast, smaller regions may be more open to specialized treatments that require more time or unique handling.
Regional Differences in Drug Delivery
Drug delivery methods are influenced not just by culture, but also by economics, insurance systems, and infrastructure. For example, biosimilars are more readily accepted in some countries depending on reimbursement structures. Meanwhile, large-scale programs — such as vaccine rollouts — highlight how fragile supply chains can be.
Cold Chain and Pandemic Lessons
Certain drugs, including attenuated vaccines, require strict cold chain maintenance. In developing regions, this presents a major challenge. The COVID-19 pandemic underscored this issue when millions of doses expired due to distribution and storage limitations. As Nick and Nigel note, a drug designed for one part of the world may face barriers to adoption in another, depending on the delivery method.
Enjoying Bio Break? Sign up to get new episodes sent to your inbox.
Related Resources

Jason McGee explores how the Rightness Trap Medtech dynamic can quietly erode enterprise value in medical device companies.

Understanding gram positive vs negative bacteria is essential when studying sterility, microbiology, and antibiotic effectiveness. While many people think the difference is only about staining, the reality is much deeper.

Nick and Nigel explore the science behind hand sanitizer formulations. They discuss how alcohol interacts with bacterial cells, why water improves its effectiveness, and what the additional ingredients in sanitizer actually do.

Scott Phillips, CEO of StarFish Medical, sits down with Peter van der Velden, Managing General Partner at Lumira Ventures, to explore the strategic thinking behind major MedTech transactions and investments.